Related Experiment Video
Updated: Nov 16, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Perioperative Immunotherapy in Muscle-invasive Bladder Cancer
Abhishek Tripathi1, Ali Raza Khaki2, Petros Grivas2
1Department of Medicine, Section of Hematology Oncology, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.
Abstract:
Immune checkpoint inhibitors (ICIs) have already been approved for the treatment of metastatic urothelial carcinoma and are now being investigated for perioperative treatment of muscle-invasive bladder cancer (MIBC). Ongoing trials are assessing ICIs as monotherapy and in combination with other treatments. Early data are promising, and long-term survival data are awaited to confirm the potential of ICIs in MIBC.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Kidney Transplant II: Surgical Procedure

